Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Anti-SARS-CoV-2 hyperimmune globulin therapy-Grifols (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Sponsors Grifols
- 09 Feb 2022 Status changed from recruiting to discontinued.
- 02 Nov 2021 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.
- 02 Nov 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Dec 2021.